Seroatlas · Human Serome Atlas

NAALAD2

N-acetylated-alpha-linked acidic dipeptidase 2

Also known as: GCPIII, NAALADASE2, NALD2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9Y3Q0
Gene
NAALAD2
Ensembl
ENSG00000077616
Chromosome
11
Canonical length
740 aa
Protein class
Enzymes, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location
Nucleoplasm
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene is a member of the N-acetylated alpha-linked acidic dipeptidase (NAALADase) gene family. The representative member of this family is the gene encoding human prostate-specific membrane antigen (PSM), which is a marker of prostatic carcinomas and is the first to be shown to possess NAALADase activity. NAALADase cleaves N-acetyl-L-aspartate-L-glutamate (NAAG), which is a neuropeptide expressed both in the central nervous systems and in the periphery and is thought to function as a neurotransmitter. The product of this gene is a type II integral membrane protein. Transient transfection of this gene confers both NAALADase and dipetidyl peptidase IV activities to mammalian cells. This gene is highly expressed in ovary and testis as well as within discrete brain areas. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2014]

Canonical amino-acid sequenceUniProt

740 residues, UniProt reviewed canonical sequence.

>Q9Y3Q0|NAALAD2
     1  MAESRGRLYL WMCLAAALAS FLMGFMVGWF IKPLKETTTS VRYHQSIRWK LVSEMKAENI
    61  KSFLRSFTKL PHLAGTEQNF LLAKKIQTQW KKFGLDSAKL VHYDVLLSYP NETNANYISI
   121  VDEHETEIFK TSYLEPPPDG YENVTNIVPP YNAFSAQGMP EGDLVYVNYA RTEDFFKLER
   181  EMGINCTGKI VIARYGKIFR GNKVKNAMLA GAIGIILYSD PADYFAPEVQ PYPKGWNLPG
   241  TAAQRGNVLN LNGAGDPLTP GYPAKEYTFR LDVEEGVGIP RIPVHPIGYN DAEILLRYLG
   301  GIAPPDKSWK GALNVSYSIG PGFTGSDSFR KVRMHVYNIN KITRIYNVVG TIRGSVEPDR
   361  YVILGGHRDS WVFGAIDPTS GVAVLQEIAR SFGKLMSKGW RPRRTIIFAS WDAEEFGLLG
   421  STEWAEENVK ILQERSIAYI NSDSSIEGNY TLRVDCTPLL YQLVYKLTKE IPSPDDGFES
   481  KSLYESWLEK DPSPENKNLP RINKLGSGSD FEAYFQRLGI ASGRARYTKN KKTDKYSSYP
   541  VYHTIYETFE LVEKFYDPTF KKQLSVAQLR GALVYELVDS KIIPFNIQDY AEALKNYAAS
   601  IYNLSKKHDQ QLTDHGVSFD SLFSAVKNFS EAASDFHKRL IQVDLNNPIA VRMMNDQLML
   661  LERAFIDPLG LPGKLFYRHI IFAPSSHNKY AGESFPGIYD AIFDIENKAN SRLAWKEVKK
   721  HISIAAFTIQ AAAGTLKEVL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NAALAD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.21
Highest tissue expression
19 nTPM

Expression across tissuesHPA

Tissue

  • pituitary gland: 19 nTPM
  • testis: 13 nTPM
  • adrenal gland: 9.7 nTPM
  • cervix: 9.3 nTPM
  • basal ganglia: 7.6 nTPM
  • hypothalamus: 7.5 nTPM

Single-cell type

  • oligodendrocyte progenitor cells: 149 nCPM
  • brain inhibitory neurons: 125 nCPM
  • other brain neurons: 65 nCPM
  • brain excitatory neurons: 61 nCPM
  • oligodendrocytes: 55 nCPM
  • bergmann glia: 38 nCPM

Immune cell

  • non-classical monocyte: 0.4 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM

Brain region

  • cerebral cortex: 13 nTPM
  • white matter: 11 nTPM
  • pons: 9.4 nTPM
  • midbrain: 9.2 nTPM
  • basal ganglia: 8.6 nTPM
  • thalamus: 8.3 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NAALAD2.

Disease | ImmuneIEDB

Conditions an epitope on NAALAD2 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.09
gnomAD pLI
0
gnomAD missense Z
0.47
DepMap mean gene effect
0.08
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NAALAD2 as an antibody target. Whether an autoantibody or antibody against NAALAD2 could matter depends on whether native NAALAD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NAALAD2 is annotated at the cell surface, where native NAALAD2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label NAALAD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/NAALAD2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...